Telescope Innovations Corp., a leader in Physical AI and Self-Driving Laboratories for pharma R&D, will join the Canadian business delegation at BIOPLUS-INTERPHEX Korea (BIX) from October 27-30, 2026. The event, where Canada is the Country of Honour, offers Telescope a platform to showcase its AI-driven lab technologies and expand collaborations in South Korea's growing biopharmaceutical market. Telescope will participate in presentations, panel discussions, and business matchmaking to advance its presence and partnerships in Asia. This engagement supports the company's goal to accelerate pharmaceutical research through automation and AI innovation.
Telescope Innovations' participation at BIOPLUS-INTERPHEX Korea 2026 comes as the health sector on Pluang shows mixed activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: out of 150 priced US health-sector stocks, 73 rose and 47 fell today. Notable movers include BFLY (Butterfly Network Inc. Class A Common Stock) at USD 7.38 with a 1-day change of +1.86% and a typical hold time of 4 days, ELAN (Elanco Animal Health Incorporated Common Stock) at USD 23.97 with a +1.78% change and a 10-day hold, and LQDA (Liquidia Corporation Common Stock) at USD 33.76 down -1.72% with a 1-day hold time.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
